Asset Details
Do you wish to reserve the book?
Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)
Do you wish to request the book?
Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B)
2012
Overview
► Repeat-dose toxicity (mice) – no vaccine related adverse findings. ► Neurobehavioral toxicity (mice) – no vaccine related adverse findings. ► Local reactogenicity (rabbits) – no vaccine related adverse findings. ► All study designs reviewed by FDA prior to implementation. ► Enabled execution of Phase 1 clinical study.
A recombinant botulinum vaccine (rBV A/B) is being developed to protect adults 18–55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, subtype B1 (BoNT/B1). Fundamental to the advanced development process is an initial demonstration of product safety in animals. A comprehensive series of studies was conducted to evaluate the general toxicity, neurobehavioral toxicity and local reactogenicity of the rBV A/B vaccine prior to first use in humans. Toxicity was evaluated in CD-1 mice vaccinated with control material and three dosages of rBV A/B with or without Alhydrogel® by intramuscular (IM) injection on Study Days 0, 28, 56 and 70 in a volume of 100μL. Total immunizing protein given in each dose was either 0, 2, 4 or 8μg/animal. Local reactogenicity was evaluated in mice at the dosages given and in New Zealand white (NZW) rabbits using the same injection volume (0.5mL) and formulations (10, 20 and 40g/mL total antigen with 0.2% (w/v) Alhydrogel®) intended for human use. The rBV A/B vaccine produced no apparent systemic or neurobehavioral toxicity and only transient mild inflammation at the injection site. Together these results indicated a favorable safety profile for rBV A/B and supported its use in a Phase 1 clinical trial.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antigens
/ Bacterial Vaccines - administration & dosage
/ Bacterial Vaccines - immunology
/ Bacterial Vaccines - toxicity
/ Botulism
/ Botulism - prevention & control
/ Drug Evaluation, Preclinical
/ Female
/ humans
/ Male
/ Mice
/ Rabbits
/ Studies
/ Toxicity
/ Vaccine
/ Vaccines
/ Vaccines, Synthetic - administration & dosage
